The disconnect between preclinical animal data and human trial outcomes remains a critical bottleneck in drug development. While rodent models have long been the industry standard, their inability to replicate human muscle physiology—such as metabolic responses, neuromuscular interactions, or disease-specific pathology—contributes to a 95% clinical attrition rate for musculoskeletal therapies.
Myomaker Bio addresses this challenge with TRL 9-validated 3D human muscle organs. These bioengineered systems integrate skeletal muscle, motor neurons, and vasculature to deliver physiologically accurate outputs. For instance, in a collaboration with a top-tier pharmaceutical company, our platform identified a late-stage compound’s off-target myotoxic effects that were undetected in animal studies, enabling an early pipeline pivot and £1.5M in cost savings.
By prioritizing human biology at the preclinical stage, we empower researchers to derisk candidates earlier, reduce reliance on animal testing, and accelerate therapies for conditions like muscular dystrophy and sarcopenia. In an era of precision medicine, models must evolve—and Myomaker Bio leads the charge.
Learn more about services.